1. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Author
-
Garvey, W Timothy, Frias, Juan P, Jastreboff, Ania M, le Roux, Carel W, Sattar, Naveed, Aizenberg, Diego, Mao, Huzhang, Zhang, Shuyu, Ahmad, Nadia N, Bunck, Mathijs C, Benabbad, Imane, Zhang, Xiaotian M, Abalos, Franklin H., Manghi, Federico C.P., Zaidman, Cesar J., Vico, Marisa L., Aizenberg, Diego, Costanzo, Pablo R., Serra, Leonardo P., MacKinnon, Ignacio J., Hissa, Miguel N., Vidotti, Maria H., Kerr Saraiva, Jose F., Alves, Breno B., Franco, Denise R., Moratto, Otavio, Murthy, Sreenivasa, Goyal, Ghanshyam, Yamasaki, Yoshimitsu, Sato, Nobuyuki, Inoue, Satoshi, Asakura, Taro, Shestakova, Marina, Khaykina, Elena, Troshina, Ekaterina, Vorokhobina, Natalia, Ametov, Alexander, Tu, Shih-Te, Yang, Chwen-Yi, Lee, I-Te, Huang, Chien-Ning, Ou, Horng-Yih, Freeman, George, Machineni, Sriram, Klein, Klara, Sultan, Senan, Parsa, Alan, Otero-Martinez, Juan, Gonzalez, Alex, Bhargava, Anuj, Brian, Susan, Ince, Carlos, Plantholt, Stephen, Cole, Jeremy, Lacour, Audrey, Vega, Damaris, de Souza, Jose, Rohlf, Jane L., St. John, Roy C., Horowitz, Barry, Audish, Hanid, Galindo, Rodolfo, Umpiperrez, Guillermo, Ard, Jamy, Curtis, Brian, Garvey, William T., Fraser, Neil J., Mandry, Jose, Mohseni, Rizwana, Mayfield, Ronald, Powell, Talessa, Vance, Carl, Ong, Stephen, Lewy-Alterbaum, Ana L., Murray, Alexander, Al-Karadsheh, Amer, Yacoub, Tamer, Roberts, Kevin, Fried, David L., Rosenstock, Julio, Pulla, Bharathi, Bode, Bruce, Frias, Juan, Klaff, Leslie, Brazg, Ronald, Van, Joanna, Tan, Anjanette, Briskin, Toby, Rhee, Margaret, Chaicha-Brom, Tira, Hartley, Paul A., Nunez, Lazaro, Cortes-Maisonet, Gregorio, Soucie, Gary, Hsia, Stanley, and Jones, Thomas
- Abstract
Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, versus placebo, for weight management in people living with obesity and type 2 diabetes.
- Published
- 2023
- Full Text
- View/download PDF